Cipla share news, announcements and annual reports
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Cipla Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1983 on BSE, Feb 1995 on NSE
Last close ₹1,387.00up ₹8.10 (0.59%)BSE ₹1,382.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,378.90.
2 Nov: open ₹1,383.00, high ₹1,391.00, low ₹1,364.60
52-week range of traded prices to 2 Nov 2026
₹1,165.70Low, 2 Apr 2026₹1,539.70High, 6 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,052 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.68
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.17
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 8.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 13,77,33662.2% delivered
Cipla share news and announcements
1,563 announcements, routine notices left out, newest first. Page 29 of 32.
Oct 2012
26 Oct · Board meeting
Inter-alia to consider Unaudited Financial Results for second quarter ended September 30, 2012.
Aug 2012
21 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2012
23 Jul · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2012.
Jun 2012
7 Jun · Corporate action
Register of Members and Share Transfer Books of the Company shall remain closed from August 03, 2012 to August 17, 2012 (both days inclusive) for the purpose of Annual General Meeting and determining the persons entitled for dividend for the year ended March 31, 2012. The dividend, subject to the approval of shareholders, will be dispatched / credited on or after August 23, 2012.7 Jun · Dividend
Board of Directors of the Company at its meeting held on June 07, 2012 has recommended payment of dividend of Rs. 2 per equity share (face value Rs. 2) for the year 2011-2012.7 Jun · Updates
Cipla Limited had informed the Exchange regarding an order passed against the Company by United States District Court, Middle District of Georgia, in a litigation relating to an animal healthcare product. The Company had filed an appeal in the United States Court of Appeals for the Federal Circuit in Washington, D.C. against this order. The Company has now received an order from the Federal Circuit wherein it has affirmed the order of the District Court with two judges ruling against the Company and one judge in favour of the Company. The Company is examining options for preferring an appeal against the aforesaid Federal Circuit order. The District Court is yet to determine the financial implication of the District Court order dated June 21, 2011.
May 2012
30 May · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2012 and Recommendation of Dividend, if any.10 May · Results
Standalone Results for the quarter ended on 31-MAR-2012 as follows: Net Sales of Rs. 181405 lacs for quarter ending on 31-MAR-2012 against Rs. 161522 lacs for the quarter ending on 31-MAR-2011. Net Profit / (Loss) of Rs. 29174 lacs for the quarter ending on 31-MAR-2012 against Rs. 21400 lacs for the quarter ending on 31-MAR-2011.2 May · Board meeting
Inter-alia to consider Unaudited Financial Results for fourth quarter ended March 31, 2012.
Mar 2012
2 Mar · Updates
This has reference to the Company's earlier disclosures regarding notices received by the Company from the National Pharmaceutical Pricing Authority, Government of India. The Company has now received further demand notices from the Government for Rs.424.64 crores towards interest upto January, 2012 on the allegedly overcharged amounts in respect of the same drugs which are subject matter of litigation in the Hon ble Supreme Court of India. These demands are contrary to the orders of the Hon'ble Supreme Court of India and the Company has received legal advice that entire amounts demanded by the Government are not tenable and sustainable.
Feb 2012
3 Feb · Board meeting
Inter-alia to consider Unaudited Financial Results for third quarter ended December 31, 2011.
Nov 2011
14 Nov · Management
As under : (1) Appointment of Additional Director : The Board of Directors at its meeting held on November 14, 2011 have appointed Dr. Ranjan Pai as an Additional Director on the Board of Directors of the Company. Dr. Ranjan Pai is the Founder and Chief Executive Officer of the Manipal Education and Medical Group (MEMG), a diversified group focusing on Education, Healthcare and Research. He is a graduate of medicine from the Kasturba Medical College, Manipal after which he obtained a Fellowship in Hospital Administration in the United States. His vast experience in the area of Healthcare, Research and Education and his strong reputation and goodwill will further strengthen and broad-base the Company's Board; (2) Appointment of Chief Financial Officer : As a part of broad-basing the Company's organisational structure, Mr. V. S. Mani has been appointed as the Chief Financial Officer of the Company. Mr. V. S. Mani succeeds Mr. S. Radhakrishnan, the present Chief Financial Officer of the Company. Mr. S. Radhakrishnan, having been nominated to the Board last year, continues to be the Executive Director of the Company. Mr. V. S. Mani is a qualified Chartered Accountant and has rich experience and knowledge of pharmaceutical industry both in the domestic and international arena. He was working for Cipla until 2002 and subsequently held positions with other pharmaceutical companies such as Glenmark, Wockhardt etc. Mr. V.S. Mani's span of expertise covers the entire gamut of Finance, Information Technology, Legal and other allied areas.14 Nov · Updates
14 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 173183 lacs for quarter ending on 30-SEP-2011 against Rs. 157988 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 30897 lacs for the quarter ending on 30-SEP-2011 against Rs. 26301 lacs for the quarter ending on 30-SEP-2010.4 Nov · Board meeting
Inter-alia to consider Unaudited Financial Results for second quarter ended September 30, 2011.
Aug 2011
24 Aug · News Verification
News Verification : The media had reports that Japanese Drugmaker Takeda is in talks to buy company's pharma business. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Cipla Limited has vide its letter inter-alia stated,"The news item is baseless, untrue and is categorically denied."5 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 155033 lacs for quarter ending on 30-JUN-2011 against Rs. 142738 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 25334 lacs for the quarter ending on 30-JUN-2011 against Rs. 25742 lacs for the quarter ending on 30-JUN-2010.3 Aug · Meeting
Annual General Meeting of the Company will be held on August 25, 2011.
Jul 2011
28 Jul · Board meeting
Inter-alia to consider Unaudited Financial Results for first quarter ended June 30, 2011.
Jun 2011
30 Jun · Updates
Company has received an order dated June 21, 2011 from a United States District Court, Middle District of Georgia against a petition filed by Merial Limited ruling that the sales of PetArmor Plus (an animal healthcare product) allegedly infringed a patent held by Merial Limited and have suspended future sales in the United States. The District Court has stayed the above order for 60 days in order to enable the Company to appeal. The Company is in the process of filing an appeal against this order. There is no determination as yet by the Court on the financial implication of the patent infringement.29 Jun · Corporate action
Register of Members and Share Transfer Books of the Company shall remain closed from August 11, 2011 to August 25, 2011(both days inclusive) for the purpose of Annual General Meeting and determining the persons entitled for the dividend for the year ended March 31, 2011.29 Jun · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 613031 lacs for year ending on 31-MAR-2011 against Rs. 535952 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 98957 lacs for the year ending on 31-MAR-2011 against Rs. 108259 lacs for the year ending on 31-MAR-2010.29 Jun · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 613516 lacs for year ending on 31-MAR-2011 against Rs. 535952 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 96039 lacs for the year ending on 31-MAR-2011 against Rs. 108149 lacs for the year ending on 31-MAR-2010.29 Jun · Dividend
Board of Directors of the Company at its meeting held on June 29, 2011, inter alia, has recommended payment of final dividend of Rs. 2 per equity share (face value Rs. 2) for the year 2010-2011 amounting to Rs. 160.58 Crores. In September 2010, the Company paid an interim dividend of 80 paise per equity share (face value of Rs. 2) for the year 2010-2011.21 Jun · Board meeting
Inter-alia to consider the Annual Audited Accounts for the year ended March 31, 2011 and Recommendation of Dividend, if any.
May 2011
6 May · Updates
5 May · Results
Standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 161522 lacs for quarter ending on 31-MAR-2011 against Rs. 131749 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 21400 lacs for the quarter ending on 31-MAR-2011 against Rs. 27553 lacs for the quarter ending on 31-MAR-2010.
Apr 2011
27 Apr · Board meeting
Inter-alia to consider Unaudited Financial Results for fourth quarter ended March 31, 2011.
Feb 2011
4 Feb · Updates
4 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 150136 lacs for quarter ending on 31-DEC-2010 against Rs. 134416 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 23269 lacs for the quarter ending on 31-DEC-2010 against Rs. 28903 lacs for the quarter ending on 31-DEC-2009.
Jan 2011
28 Jan · Legal
Company have received a query from the Financial Daily regarding stake sale by Cipla. In this connection, the Company had categorically denied this news vide letter dated December 20, 2010. The Company would once again like to reiterate that these rumours are absolutely baseless and are purely speculative in nature and the Company has no intention whatsoever to do any stake sale.27 Jan · Board meeting
Inter-alia to consider Unaudited Financial Results for third quarter ended December 31, 2010.
Dec 2010
28 Dec · Updates
Fresh notices received from National Pharmaceutical Pricing Authority, Government of India. The Company has now received further demand notices from the Government demanding an amount of Rs. 47.70 crores in respect of the drug Salbutamol and an amount of Rs. 25.46 crores in respect of the drug Ciprofloxacin. These demands are contrary to the orders of the Hon'ble Supreme Court of India and the Company has received legal advice that entire amounts demanded by the Government are not tenable and sustainable.